Study of Genetic Subtypes in Peripheral T-cell Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows people with peripheral T-cell lymphoma (PTCL) to learn how different genetic subtypes of the disease affect their outlook and treatment response. Researchers will collect medical information, genetic test results, and long-term follow-up data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with peripheral T-cell lymphoma (a type of blood cancer) through a tissue biopsy.
- Your tumor needs to have genetic testing (next-generation sequencing) to find its molecular subtype. If you were diagnosed after June 2026, this testing is required. If you were diagnosed earlier (January to June 2026), you can still join as long as tumor tissue is available for testing.
- You must be 18 years old or older.
- You cannot be pregnant, breastfeeding, or planning pregnancy without effective birth control.
- You must be able to understand the study and sign a consent form, and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
This trial tests if choosing treatment based on your lymphoma's genetic profile can improve outcomes for people newly diagnosed with peripheral T-cell lymphoma. It involves analyzing your tumor DNA to find the best therapy for you.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This study, run by Massachusetts General Hospital, is collecting information from people around the world who have certain types of T-cell or NK-cell lymphoma. It aims to learn more about these cancers and how they are managed.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.